How the One Big Beautiful Bill Act (OBBBA) Will Reshape Clinical Research in America
- Dec 11, 2025
- 3 min read
Updated: Jan 30
The Hidden Impact of OBBBA on Clinical Trials: What Research Leaders Need to Know
When the One Big Beautiful Bill Act (OBBBA) was signed into law on July 4, 2025, most headlines focused on politics, tax cuts, and healthcare restructuring. But tucked inside this sweeping legislation is a quieter story , one that directly affects clinical research sites, Academic Medical Centers (AMCs), and health systems across the country.
Clinical trials don’t happen in a vacuum. They depend on financial incentives, patient access, staffing capacity, and the broader health-system environment. OBBBA touches all four.
Here’s a clear look at how this new policy era may change the daily realities of clinical research organizations.
R&D Expensing Is Back , And It Could Boost Early-Phase Research
One of the most impactful (and widely confirmed) elements of OBBBA is the restoration of immediate expensing for domestic research and experimental (R&E) costs.
Why this matters
For years, companies had to amortize R&E expenses over five years, slowing innovation and tying up capital. OBBBA reverses that:
Companies can now deduct 100% of R&E costs in the same year they’re incurred.
Liquidity improves, especially for small biotech firms.
Sponsors regain financial flexibility to launch more early-phase studies.
What this means for sites and AMCs
Restoring immediate expensing improves cash flow for sponsors, which may incentivize more investment in early-phase research, potentially increasing demand for site participation and study startups.
Medicaid Restructuring Will Make Recruitment and Diversity More Challenging
OBBBA’s Medicaid provisions, including expanded work requirements, more frequent eligibility reviews, and reductions in federal spending as projected by the CBO, could shrink coverage and complicate access for patients who would otherwise be potential research participants.
Likely impacts
Harder recruitment: Fewer patients regularly accessing care means fewer opportunities for referral or prescreening.
Reduced diversity: Populations most affected by Medicaid cuts , like rural, low-income, and minority communities, are the very populations research organizations are working hard to reach.
More participant churn: Administrative changes mean more patients may lose and regain eligibility during a study.
Higher operational burden: Coordinators will spend more time checking coverage, managing documentation, and troubleshooting eligibility issues.
Recruitment and retention, already two of the biggest pain points in clinical research, may become even more complicated under this new policy.
Hospitals and AMCs May Face Budget Pressure — Which Often Impacts Research Capacity
OBBBA introduces many structural changes affecting hospital finances. While none are written specifically for research, AMCs and health systems will feel the downstream effects.
Why it matters
Research infrastructure , including trial units, coordinators, regulatory teams, investigator time , is often categorized as strategic but non-revenue-generating.
When budgets tighten, these areas are historically the first to experience:
Hiring freezes
Reduced operational capacity
Slower study start-up
Less institutional support for new trials
Even modest financial pressure can ripple through large research programs.
Rural environments
The OBBBA includes provisions to stabilize rural hospitals, which matters because these facilities serve as essential access points for decentralized or community-based research. But stabilization is not the same as growth — research capacity won’t automatically expand.
Administrative Burden Will Increase — Especially for Studies Involving Medicaid Populations
Even for patients who remain eligible for Medicaid, OBBBA introduces new administrative hurdles.
Expect:
More eligibility checks
More documentation requirements
More frequent redeterminations
More variability in coverage during long-term studies
For sites and AMCs, this translates into:
Additional coordinator workload
More complex screening processes
Higher risk of protocol deviations
Greater need for support tools and technologies
OBBBA doesn’t just shift policy . It shifts operational reality.
What Sites and Health Systems Should Prepare For
The next 12–24 months will bring a mix of opportunities and challenges.
Upside
More sponsor investment, especially in early-phase trials
Improved liquidity for biotech-driven research
Potential pipeline expansion from increased R&D funding capacity
Downside
More difficult recruitment and retention
Threats to trial diversity goals
Operational strain inside AMCs and hospital systems
Greater need for workflow efficiency and digital infrastructure
OBBBA doesn’t stop clinical research , but it does change the environment in which it operates.
How Research Leaders Can Get Ahead
Here are five strategic steps that sites, AMCs, and networks should consider now:
1. Strengthen sponsor partnerships
Sponsors with healthy pipelines will become even more important.
2. Invest in technology that reduces friction
CTMS, eSource, eReg/eISF, participant communication tools, and automated workflows will be essential for managing churn.
3. Diversify recruitment strategies
Especially for studies that historically rely on Medicaid-covered participants.
4. Elevate research as a strategic priority within your institution
Advocacy matters. Research programs must not become collateral damage during budget shifts.
5. Track regulatory guidance closely
Implementation details will determine how some provisions actually function in practice.
Final Thought
OBBBA represents a new era for U.S. healthcare , one that blends opportunity and uncertainty. For clinical research sites, AMCs, and health systems, the challenge ahead is not simply to adapt, but to innovate.
Policy shapes the environment. Research organizations shape the future.
Comments